By Gary Mackenzie – Guest Contributor Leaflit.media
After years of infringement notices, regulatory warnings and escalating scrutiny, Australia’s medicinal cannabis industry is now watching one of the most significant legal battles the sector has faced move deeper into the Federal Court system.
Montu and its telehealth clinic Alternaleaf remain locked in an increasingly serious dispute with the Therapeutic Goods Administration over alleged advertising breaches linked to the promotion of medicinal cannabis services.
The case centres on alleged breaches of Australia’s therapeutic advertising laws, including how medicinal cannabis services and related terminology were communicated publicly during the explosive growth of cannabis telehealth in Australia.
And while the legal arguments focus on advertising compliance, the broader industry understands the implications run much deeper.
This case is rapidly becoming a test of how far medicinal cannabis businesses in Australia are allowed to communicate publicly within a healthcare framework that many operators argue has struggled to keep pace with the speed of industry growth.
…/…
The Federal Court Proceedings
In 2024, the TGA formally initiated Federal Court proceedings against Montu, Alternaleaf and managing director Christopher Strauch personally. (tga.gov.au)
The regulator alleges unlawful advertising of medicinal cannabis services between January 2022 and April 2024, including references to medicinal cannabis, plant medicine terminology, health conditions and patient-focused messaging. The allegations also extend personally to Strauch, with claims he aided or procured the alleged breaches. (tga.gov.au)
The significance of the case extends well beyond Montu itself.
By pursuing both the company and its managing director personally, the regulator has sent a strong message across the broader medicinal cannabis sector regarding enforcement expectations.
At the same time, the length and intensity of the dispute suggests neither side views this as a minor compliance disagreement.
The legal costs alone are likely substantial on both sides:
- Federal Court litigation
- barristers and regulatory counsel
- compliance reviews
- discovery processes
- public relations management
- internal restructuring
- ongoing advisory costs
And despite that, the matter continues escalating.
Which suggests this case is no longer simply about advertising technicalities.
It has become a battle over precedent.
Read the full article
https://www.linkedin.com/pulse/montu-case-federal-court-battle-could-reshape-medicinal-tibnc/
